Stock comparison
LeMaitre Vascular
Novartis AG
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
NVS
Novartis AG
Market cap
$290.64B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | NVS | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 62C | LMAT |
| Benjamin Graham | 89A | 69B | LMAT |
| Philip Fisher | 81C | 53C | LMAT |
| Peter Lynch | 67B | 35D | LMAT |
| Joel Greenblatt | 56D | 46D | LMAT |
| Charlie Munger | 68D | 69C | NVS |
| Terry Smith | 69D | 66B | LMAT |
Side-by-side metrics
| Metric | LMAT | NVS |
|---|---|---|
| Market cap | $2.23B | $290.64B |
| P/E (TTM) | 37.1x | 21.3x |
| EV/EBIT | 36.6x | 19.2x |
| ROIC (TTM) | 9.43% | 14.89% |
| Gross margin | 72.39% | 75.13% |
| Net margin | 24.35% | 24.31% |
| Revenue CAGR 5y | 12.75% | 5.66% |
| EPS CAGR 5y | 19.04% | -9.29% |
| Debt / Equity | 0.5x | 1.2x |
| Dividend yield | 0.84% | 3.12% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- EPS CAGR 5y19.04%vs -9.29%+149%
- Debt / Equity0.5xvs 1.2x+62%
- Revenue CAGR 5y12.75%vs 5.66%+56%
NVS leads on
- Market cap$290.64Bvs $2.23B+99%
- Dividend yield3.12%vs 0.84%+73%
- EV/EBIT19.2xvs 36.6x+48%
- P/E (TTM)21.3xvs 37.1x+43%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.